Clinical Events after Deferral of LAD Treatment Guided by FFR or iFR

iFR is a safe alternative for lesion deferral even when it comes to the left anterior descending artery (LAD). What is more, patients deferred with iFR showed significantly fewer events than patients deferred using FFR.

La performance diagnóstica del iFR hace temblar al FFRNeither clinical cardiologists nor interventionists feel comfortable deferring LAD treatment, because it is often perceived as high risk. If functional assessment is non-significant, they will look for an excuse to perform IVUS or any other thing to end up treating a lesion that, despite the angiography, is not ischemic.

 

Using the DEFINE-FLAIR (Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularization) the authors describe when lesions are differed using invasive functional assessment using either fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR).


Read also: How long should we wait with asymptomatic aortic stenosis and preserved LVEF?


Combined major events rate (MACE) was compared at one year between patients whose LAD lesions had been deferred using FFR vs iFR. MACE was defined as a combination of cardiovascular death, acute myocardial infarction and unplanned revascularization. Both patients and physicians in charge of follow up were blinded to whether the decision was made based on FFR or iFR.

 

In all, 872 patients had angiographic LAD lesions: 421 guided by FFR and 451 guided by por iFR were deferred.


Read also: Safety in Abdominal Aortic Aneurysm Surveillance Programs.


Events rate was significantly lower when using iFR compared against FFR (2.44% vs. 5.26%; HR: 0.46; CI 95%: 0.22 to 0.95; p=0.04). This was driven by significantly lower unplanned revascularization with iFR (2.22% iFR vs. 4.99% FFR, p=0.03) and lower infarction rate, non-significant, not numerically though (0.44% iFR vs. 2.14% FFR, p=0.06).

 

Original Title: Clinical Events After Deferral of LAD Revascularization Following Physiological Coronary Assessment.

Reference: Sayan Sen et al. J Am Coll Cardiol 2019;73:444–53.

 

444-abierto.full


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...